Anagenics Limited (ASX:AN1) Filings

Anagenics Limited

Filings

FilingDateTypeFiled with
AGM UpdateNov 19, 2026Meeting noticeASX
Notices under sections 203D and 249D of the Corporations ActNov 19, 2026Other filingsASX
Application for quotation of securities - AN1Nov 15, 2026FinancingASX
Proposed issue of securities - AN1Nov 11, 2026FinancingASX
Anagenics to Acquire Bio-First Skincare BrandNov 10, 2026Acquisition or disposalASX
Sale of Intellectual Property and Earn-Out ArrangementNov 4, 2026Acquisition or disposalASX
Pause in TradingNov 4, 2026Trading halt or suspensionASX
AN1 - Appendix 4C & Activity Report for Q1 FY2027Oct 22, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 5, 2026Meeting noticeASX
AN1 FY26-Appendix-4E-Aug 28, 2026ResultsASX
AN1 - Appendix 4G JUN 2026Aug 28, 2026Other filingsASX
AN1 2026 Annual ReportAug 28, 2026Annual reportASX
Appendix 4C & Activity Report for Q4 FY2026Jul 29, 2026Quarterly reportASX
Change of AuditorJul 27, 2026Management or board changeASX
AN1 - Appendix 4C & Activity Report for Q3 FY2026Apr 27, 2026Quarterly reportASX
Anagenics - 1H FY26 Result HighlightsFeb 24, 2026ResultsASX
Appendix 4D 1H FY26 DEC 2025Feb 24, 2026Interim reportASX
Appendix 4C & Activity Report for Q2 FY2026Jan 29, 2026Quarterly reportASX
Placement of SharesDec 9, 2025FinancingASX
Trading HaltDec 7, 2025Trading halt or suspensionASX
Appendix 4C & Activity Report for Q1 FY2026Oct 30, 2025Quarterly reportASX
AN1 - FY 2025 PresentationAug 28, 2025ResultsASX
AN1 FY25-Appendix-4E-Preliminary-Final-ReportAug 27, 2025ResultsASX
Activity Report & Appendix 4C Q4 FY2025Jul 28, 2025Quarterly reportASX
YSB Bouf Haircare Continues Strong PerformanceJun 27, 2025Operations updateASX
York Street Brands Product LaunchJun 4, 2025Operations updateASX
AN1 - 3Q25 PresentationMay 4, 2025Quarterly reportASX
Reinstatement to QuotationMay 2, 2025Trading halt or suspensionASX
AN1 - Pre-reinstatement DisclosureMay 2, 2025Other filingsASX
AN1 3Q25 Activity ReportMay 1, 2025Quarterly reportASX
Appendix 4C Cash Flow ReportMay 1, 2025Quarterly reportASX
Long Term Suspended EntitiesApr 9, 2025Trading halt or suspensionASX
AN1 - 1H25 UpdateFeb 27, 2025Interim reportASX
AN1 - Appendix 4D 1H FY2025Feb 27, 2025Interim reportASX
Update on 2Q25 Activity ReportFeb 10, 2025Quarterly reportASX
Q2 F25 Activity Statement and Appendix 4CJan 31, 2025Quarterly reportASX
Restructuring Update & Resignation of DirectorOct 31, 2024Operations updateASX
Q1 F25 Activity Statement and Appendix 4COct 31, 2024Quarterly reportASX
Market UpdateOct 2, 2024Acquisition or disposalASX
Suspension from Official QuotationSep 3, 2024Trading halt or suspensionASX
Pause in TradingSep 2, 2024Trading halt or suspensionASX
FY24 4E PresentationAug 30, 2024ResultsASX
Appendix 4E and Preliminary Final ReportAug 30, 2024ResultsASX
Company Update License Partnership AnnouncementJul 23, 2024Operations updateASX
Appendix 4C Cash Flow & Activities ReportJul 23, 2024Quarterly reportASX
Midkine Antibody Licensing DealMay 24, 2024Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow ReportApr 28, 2024Quarterly reportASX
Organisational ChangesMar 7, 2024Management or board changeASX
H1 FY24 Results and Corporate UpdateFeb 26, 2024ResultsASX
Appendix 4D and Half Year ReportFeb 26, 2024Interim reportASX
Investor PresentationFeb 6, 2024Other filingsASX
Completion of PlacementFeb 6, 2024FinancingASX
Appendix 4C and Quarterly Activity ReportOct 30, 2023Quarterly reportASX
Business UpdateOct 1, 2023Acquisition or disposalASX
Acquisition of Face MediGroup PresentationAug 22, 2023Acquisition or disposalASX
Anagenics to Acquire Face MediGroupAug 22, 2023Acquisition or disposalASX
FY23 Financial Performance and Business UpdateJun 27, 2023Operations updateASX
CEO AppointmentMar 28, 2023Other filingsASX
Results of Institutional Entitlement OfferFeb 15, 2023FinancingASX
Entitlement Offer and Company UpdateFeb 13, 2023FinancingASX
Corporate Update and AcquisitionDec 8, 2022Acquisition or disposalASX
Appendix 4E and FY22 Financial ReportAug 24, 2022ResultsASX
Advangen Japan Divestment and Earn-Out AgreementJul 25, 2022Acquisition or disposalASX
Appointment of Exec Director, Corporate and Trading UpdateJul 7, 2022Management or board changeASX
New Leadership Driving Business TransformationMar 15, 2022Other filingsASX
Anagenics Appoints CEOFeb 28, 2022Other filingsASX
Anagenics Board and Leadership TransitionFeb 15, 2022Other filingsASX
Second Supply Agreement for Anagenics FGF5 InhibitorsDec 23, 2021Other filingsASX
BLC Cosmetics Acquisition CompletedNov 1, 2021Acquisition or disposalASX
Investor WebinarSep 26, 2021Other filingsASX
HNG: BLC Cosmetics to merge with CellmidSep 15, 2021Other filingsASX
Cellmid to Acquire BLC Cosmetics Pty LtdSep 15, 2021Acquisition or disposalASX
Appendix 4E and FY21 Financial ReportAug 19, 2021ResultsASX
Cellmid Reports Record QVC SalesJun 16, 2021Other filingsASX
Supply Agreement for Cellmids FGF5 InhibitorsJun 8, 2021Other filingsASX
Chinese Import Permits ReceivedApr 30, 2021Other filingsASX
Agreement Signed for Sale of Lyramid LimitedApr 29, 2021Other filingsASX
Supplementary ProspectusMar 31, 2021Offer documentASX
Rights Issue Closed with Strong DemandMar 31, 2021FinancingASX
Rights Issue ProspectusMar 8, 2021FinancingASX
Rights IssueMar 7, 2021FinancingASX
Cellmid Publishes Data on Novel Proprietary FGF5 AptamerFeb 8, 2021Other filingsASX
Cellmid Receives First Order From Chinese DistributorJan 24, 2021Other filingsASX
Cellmid Signs 10 Year Chinese Distribution AgreementDec 13, 2020Other filingsASX
Growth Strategy PresentationNov 11, 2020Other filingsASX
FY20 Financial ResultsAug 27, 2020ResultsASX
Appendix 4E and FY20 Financial ReportAug 27, 2020ResultsASX
CDY Signs Agreement With Premium Salon Distributor in USAJul 28, 2020Other filingsASX
Response to ASX Aware QueryJul 9, 2020Explanation requestASX
Cellmid Signs Exclusive Agreement For Sars-Cov-2 LaboratoryJul 8, 2020Other filingsASX
Extension Of Wondfo Rapid Test Distribution AgreementJul 2, 2020Other filingsASX
Cellmid Reports on Strong QVC Sales EventJun 15, 2020Other filingsASX
Cellmid Reports on Results of The Doherty Institute TestingJun 14, 2020Other filingsASX
CDY signs Introducer Agreement to broaden product offeringJun 4, 2020Other filingsASX
Appointment of Dr Dominic Burg as Chief Operating OfficerJun 1, 2020Management or board changeASX
Cellmids Alopecia Patent Allowed in Australia and JapanApr 24, 2020Other filingsASX
Independent Test Results For The Wondfo SARS-CoV-2 TestApr 22, 2020Other filingsASX
Cellmids Shipment of SARS-CoV-2 Tests ReceivedApr 14, 2020Other filingsASX
Reinstatement to Official QuotationApr 7, 2020Trading halt or suspensionASX
Response to ASX Query LetterApr 6, 2020Explanation requestASX
Market Update on COVID-19Mar 27, 2020Other filingsASX
Appendix 4D, Half Year Accounts and PresentationFeb 26, 2020Interim reportASX
Cellmids Evolis Patent to be Granted in ChinaFeb 3, 2020Other filingsASX
Appendix 4C and Notes to Appendix 4CJan 29, 2020Quarterly reportASX
Key Midkine Antibody Patents Granted in the US and EuropeJan 5, 2020Other filingsASX
Cellmid Reports on QVC SalesDec 5, 2019Other filingsASX
Cellmid Signs Trading Agreement With API/PricelineNov 5, 2019Other filingsASX
New TV Shopping Agreement for EvolisOct 13, 2019Other filingsASX
New Evolis Distribution & Supply Agreements - China & EuropeOct 1, 2019Other filingsASX
FY2019 Financial ResultsAug 28, 2019ResultsASX
Patent for Improved Midkine Antibody Allowed in EuropeAug 22, 2019Other filingsASX
CDY Signs Distribution Agreement for EVOLIS in South KoreaAug 5, 2019Other filingsASX
Response to Appendix 4C QueryAug 1, 2019Quarterly reportASX
Cellmid Sets Another Sales Record in Q4 FY2019Jul 4, 2019Other filingsASX
Cellmids Evolis Registered in European Union (EU)Apr 30, 2019Other filingsASX
Minimum Holding Share Buy-BackMar 18, 2019Treasury share statusASX
Appendix 4D, Half Year Accounts and Strategy UpdateFeb 21, 2019Interim reportASX
Significant New Findings Published on MidkineFeb 7, 2019Other filingsASX
Cellmid Expects Record Sales in Q2 FY2019Dec 11, 2018Other filingsASX
Cellmid Appoints Exclusive New Zealand DistributorNov 18, 2018Other filingsASX
New Patents for Midkine Antibodies in USA and EuropeNov 6, 2018Other filingsASX
Ikon Legal Action - DecisionNov 2, 2018Other filingsASX
Cellmids Evolis Successfully Launched in USA storesOct 31, 2018Other filingsASX
Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018Other filingsASX
Lead Antibody Effective in Rare Chronic Kidney DiseaseSep 12, 2018Other filingsASX
Cellmid Share Purchase Plan CompletionSep 2, 2018FinancingASX
Evolis USA Distribution UpdateAug 30, 2018Other filingsASX
Preliminary Final ReportAug 24, 2018ResultsASX
Cleansing Notice and Appendix 3BAug 6, 2018FinancingASX
Cellmid Share Purchase PlanJul 31, 2018FinancingASX
Cellmid Share Placement Raises $9MJul 30, 2018FinancingASX
CELLMID UPDATES ON DISTRIBUTION OF EVOLISJul 10, 2018Other filingsASX
CELLMID TO COMMENCE SELLING OF EVOLIS INTO CHINESE MARKETMay 2, 2018Other filingsASX
CELLMID SECURES BLOOMINGDALES USA PARTNERSHIP FOR EVOLISApr 23, 2018Other filingsASX
Appendix 4C - quarterlyApr 22, 2018Quarterly reportASX
CELLMID SIGNS DISTRIBUTION AGREEMENT FOR FILLERINAApr 4, 2018Other filingsASX
Appendix 4D and Half Year AccountsFeb 21, 2018Interim reportASX
RECORD 2M SALES FOR CELLMID FGF5 INHIBITORSJan 9, 2018Other filingsASX
CELLMID QUARTERLY OPERATIONAL UPDATEJan 8, 2018Other filingsASX
CELLMID PLACEMENT TO STRATEGIC INVESTORDec 15, 2017FinancingASX
CELLMID SECURES NEW US RETAIL PARTNER FOR EVOLISDec 6, 2017Other filingsASX
CELLMID OPENS FIRST CONCEPT STORE IN TOKYOOct 25, 2017Other filingsASX
PROPOSED CONSOLIDATION OF SECURITIESOct 23, 2017Other filingsASX
CELLMID RECEIVES $947K R&D TAX CREDITOct 2, 2017Other filingsASX
CELLMID COMPLETES US CONSUMER STUDYAug 20, 2017Other filingsASX
CELLMID SECURES PREMIUM US RETAIL CHANNEL FOR EVOLISAug 2, 2017Other filingsASX
Nature Paper MK in MelanomaJul 3, 2017Other filingsASX
CELLMIDS FGF5 INHIBITOR CLINICAL STUDY PUBLISHEDMar 2, 2017Other filingsASX
Cellmid to Refinance R&D Loan FacilityMar 1, 2017Other filingsASX
MIDKINE ALOPECIA PATENT EUROPEAN ALLOWANCEFeb 6, 2017Other filingsASX
CELLMIDS USA MIDKINE PATENT FOR ALOPECIA ALLOWEDJan 30, 2017Other filingsASX
Appendix 4CJan 23, 2017Quarterly reportASX
CELLMID RECEIVES AUSTRALIAN GOVT GRANT FOR MIDKINE PROGRAMMEJan 18, 2017Other filingsASX
Cellmid Updates on CxBladder LicenseDec 12, 2016Other filingsASX
Cellmid receives 831K R&D tax creditNov 29, 2016Other filingsASX
USA launch of evolisNov 2, 2016Other filingsASX
ASX Market Release - ReinstatementOct 31, 2016Other filingsASX
CELLMID RECORDS HIGHEST EVER QUARTERLY SALES FOR EVOLISOct 10, 2016Other filingsASX
Midkine Antibodies Show Anti-Tumor Activity In Brain CancerOct 5, 2016Other filingsASX
European Midkine Patent For Surgical Adhesion AllowedSep 22, 2016Other filingsASX
New Publication for Cellmids Midkine AntibodyAug 9, 2016Other filingsASX
Transcript of Cellmid Investor Briefing CallJul 29, 2016Other filingsASX
CDY: Ikon Legal ActionJul 22, 2016Other filingsASX
USA Distribution Partnership for Cellmids EvolisJul 19, 2016Other filingsASX
MK antibody publication and patent in bone healingJun 24, 2016Other filingsASX
Midkine Strategy UpdateApr 8, 2016Other filingsASX
Response to ASX QueryMar 30, 2016Explanation requestASX
Cellmid to Refinance RnD LoanFeb 26, 2016Other filingsASX
Cellmid receives $1.12M R&D Tax CreditFeb 11, 2016Other filingsASX
Key Antibody Patent Granted in EuropeFeb 10, 2016Other filingsASX